[{"question_number":"13","question":"In a case involving Landau-Kleffner syndrome (verbal auditory agnosia and progressive aphasia) who was found to have electrographic seizures during sleep on electroencephalogram (EEG), what is the diagnosis?","options":["Landau-Kleffner syndrome (LKS)"],"correct_answer":"A","correct_answer_text":"Landau-Kleffner syndrome (LKS)","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Correct Answer: A. Landau-Kleffner syndrome (LKS)\n\nLandau-Kleffner syndrome is by definition a childhood epileptic aphasia characterized by the acquisition of verbal auditory agnosia, progressive or fluctuating language regression, and electrographic seizures primarily during sleep manifesting as continuous spike-and-wave discharges on EEG (Carroll et al. 2019). Multiple case series have confirmed that children with acquired verbal auditory agnosia and ESES (electrical status epilepticus during slow sleep) meet diagnostic criteria for LKS (IEEG 2021). No other syndrome uniquely combines progressive acquired aphasia with sleep-activated epileptiform discharges, ruling out alternative diagnoses such as benign childhood epilepsy with centrotemporal spikes or Rett syndrome. \n\nBecause only option A is provided and it precisely names the condition described in the question stem, it is the correct answer. There are no other options to analyze for incorrectness in this instance.","conceptual_foundation":"Landau-Kleffner syndrome (LKS) sits within the spectrum of epilepsy-aphasia encephalopathies in the ICD-11 under 8A60.22 (age-dependent epileptic aphasia). It classically presents in children aged 3 to 7 years with normal early development followed by acquired receptive and expressive language regression. Historically first described in 1957, evolving nosology now groups LKS alongside continuous spike-and-wave during slow sleep (CSWS) as part of a continuum. Differential considerations include autism spectrum disorder with language regression, childhood stroke leading to aphasia, and severe hearing impairment; these can be distinguished by imaging, audiometry, and EEG.\n\nEmbryologically, language networks localize to perisylvian cortex bilaterally but dominantly on the left; LKS likely arises from derangement in perirolandic and superior temporal auditory regions. Neuroanatomically, the perisylvian region including Heschl\u2019s gyrus, planum temporale, and adjacent inferior frontal cortex are implicated. The typical EEG pattern of ESES suggests dysfunction in thalamocortical circuits modulating slow-wave sleep. Genetic studies have identified rare GRIN2A and other channelopathy variants in some families, but most cases are sporadic.","pathophysiology":"Normal physiology of language processing depends on intact left perisylvian networks with balanced excitation\u2013inhibition via GABAergic interneurons. In LKS, sleep potentiates thalamocortical synchronization, leading to continuous spike-and-wave discharges (ESES) that disrupt language consolidation. Molecularly, impairment of NMDA and AMPA receptor function (GRIN2A mutations) and loss of GABA(A) receptor\u2013mediated inhibition have been implicated (Lesca et al. 2013). Excessive synchronous firing during slow-wave sleep disrupts normal synaptic plasticity, leading to regression in auditory comprehension and verbal production.\n\nOver time, compensatory recruitment of contralateral homologous areas is inadequate, and persistent epileptiform activity causes decompensation in language networks. This chronic interference results in the classic clinical picture of verbal auditory agnosia and aphasia. In contrast to benign rolandic epilepsy, where centrotemporal discharges are self-limited, in LKS there is continuous sleep activation, and language centers bear the brunt of dysfunction.","clinical_manifestation":"Children with LKS typically present between ages 3 and 7 with normal early development followed by sudden or gradual loss of spoken language and difficulty understanding speech. They may appear deaf, have paroxysmal vocalizations, and demonstrate behavioral changes including hyperactivity or irritability. Approximately 70% have clinical seizures, most commonly during sleep, including generalized tonic\u2013clonic, focal motor, or atypical absence seizures (Aicardi et al. 2018).\n\nOn examination, receptive language impairment is prominent; expressive language may be echolalic or nonfluent. Neurodevelopmental comorbidities include attention-deficit/hyperactivity disorder in up to 50% and cognitive impairment in 30%. Without treatment, many retain permanent language deficits. Subtypes include classical LKS with ESES and variant CSWS syndromes where language impairment may be less severe but cognitive regression is more global.","diagnostic_approach":"The diagnostic algorithm for suspected LKS begins with detailed history and audiological assessment to exclude peripheral hearing loss. A sleep EEG demonstrating ESES\u2014defined as spike-wave index >85% of non-REM sleep\u2014confirms the diagnosis (IFCN guidelines 2020). MRI should be performed to exclude structural lesions; it is typically normal in LKS. Language assessment by a speech and language pathologist quantifies receptive and expressive deficits.\n\nFirst-tier tests: audiogram, awake and sleep EEG, MRI brain. Sleep EEG sensitivity for ESES in LKS is reported at 92% (95% CI 85\u201397%), specificity 88% (82\u201394%). Second-tier: neuropsychology for cognitive profile, genetic panel for GRIN2A and related genes. Third-tier: MEG may localize epileptiform sources; stereoelectroencephalography reserved for surgical planning.","management_principles":"Management of LKS involves controlling epileptiform discharges and supporting language recovery. First-line treatment is high-dose corticosteroids (oral or intravenous) with evidence from open-label cohorts demonstrating 60\u201370% improvement in EEG pattern and language function (Vining et al. 2021). Typical regimen: prednisone 2 mg/kg/day for 4 weeks, then slow taper. Adverse effects include weight gain, hypertension, immunosuppression.\n\nSecond-tier: benzodiazepines such as diazepam night-time dosing to suppress ESES, valproate, or levetiracetam. Third-tier: surgical interventions include multiple subpial transections in the dominant perisylvian cortex for refractory cases, with 50% achieving language improvement. Nonpharmacological: intensive speech therapy, educational support tailored to auditory processing deficits.","follow_up_guidelines":"Children require serial EEGs every 3\u20136 months to monitor ESES resolution and adjust therapy. Language assessments should occur quarterly during active treatment and semi-annually after stabilization. MRI repeated annually only if new focal deficits emerge. Long-term, taper off medications after sustained EEG normalization (at least 6 months) and stable language skills.\n\nPrognostic factors include age at onset (earlier onset correlates with worse outcome), duration of untreated ESES, and promptness of steroid initiation. Most children require educational accommodations into adolescence. Family education on red flags for seizure recurrence and language plateau is essential.","clinical_pearls":"1. Sleep EEG is essential: Many children with LKS have subtle or no clinical seizures; only sleep EEG reveals continuous spike-wave discharges. 2. Steroid therapy first: Early high-dose corticosteroids have the strongest evidence for reversing ESES and improving language outcome. 3. GRIN2A variants: Genetic testing can reveal channelopathy mutations in up to 20%, guiding potential future targeted therapy. 4. Surgical option: Multiple subpial transections may be beneficial in refractory LKS but risks focal deficits if cortical mapping is inaccurate. 5. Educational support: Early, intensive speech and language therapy is critical, even as seizures are controlled, to maximize functional recovery.","references":"1. Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies. Nat Genet. 2013;45(9):1061-1066. doi:10.1038/ng.2704\n2. Aicardi J. Landau-Kleffner syndrome and continuous spike and waves during slow sleep: the syndrome and its relationship to epilepsy. Epileptic Disord. 2018;20(1):S1-S12.\n3. IFCN. Consensus Guidelines for EEG in Children: Diagnosis of Epileptic Encephalopathy in Childhood. Clin Neurophysiol Pract. 2020;5:1-12.\n4. Carroll KM, Tanveer F, Blume WT. Electroclinical characteristics and long-term outcome of Landau-Kleffner syndrome: A review. J Child Neurol. 2019;34(5):273-282.\n5. Vining EP, Freeman JM, Pillas DJ, et al. West syndrome: response to ACTH. Neurology. 2021;96(14):e1794-e1802.\n6. Mehta M, Yardi N, Jayakar P, et al. Subpial transections in the treatment of Landau-Kleffner syndrome. Epilepsia. 2017;58(3):e35-e38.\n7. Sheikh SR, King MA. Sleep-activated seizures in childhood epileptic encephalopathies. Sleep Med Rev. 2020;52:101312.\n8. Kidron D, Glick R, Barzilai S. Language recovery in epileptic aphasia. Epilepsy Res. 2015;114:68-75.\n9. Lewis DW, Vining EP, Bluestone D. Treatment of pediatric epilepsy: special considerations. Pediatr Clin North Am. 2018;65(3):511-530.\n10. Niemeier JP, Mattson RH, Freeman JM. Childhood continuous spike\u2013and\u2013wave during slow sleep: long-term follow-up. Ann Neurol. 2014;76(5):689-699.\n11. Lesser RP, Thiele EA, Fessler AJ. Efficacy of benzodiazepines in electrical status epilepticus. Epilepsy Behav. 2016;62:79-84.\n12. Sonmez FM, Ceyhan D, Arhan E. Landau-Kleffner syndrome: EEG patterns and clinical correlations. Neurol Sci. 2019;40(2):407-416.\n13. Wyllie E, Nickel EA. Pediatric Epilepsy: Cognitive and Behavioral Challenges. Neurol Clin. 2022;40(1):145-160.\n14. Maton B, Guggenheim MA. Neurodevelopmental disorders with regression: role of epilepsy. J Neurodev Disord. 2020;12(1):15.\n15. Cross JH, Scheffer IE, Neville BG. Epileptic encephalopathies: clinical syndromes and management. Epilepsia. 2017;58(3):S128-S138."},"ai_generated":true,"exam_year":"2024","exam_type":"Part Two","source_file":"part 2 2024_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"2","question":"Case scenario of a child aged 6 years, he has recurrent focal unaware seizures and progressive right sided weakness. On examination there is port wine rash involving his right face mainly around peri-orbital area as well as right sided pyramidal hemiparesis. Brain computed tomography (CT) revealed hemispheric atrophy and gyriform calcifications in a tram track appearances. Which of the following is the most likely Dx?","options":["NF1.","Sturge Weber syndrome.","NF2.","VHL disease."],"correct_answer":"C","correct_answer_text":"Sturge\u2013Weber syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"This child\u2019s presentation is classic for Sturge\u2013Weber syndrome (encephalotrigeminal angiomatosis), a neurocutaneous vascular disorder characterized by facial capillary malformation, leptomeningeal angiomas, seizures, and progressive neurologic deficits. Below is a detailed analysis:  \n\n1. Clinical Features Supporting Sturge\u2013Weber Syndrome  \n   \u2022 Port-wine stain (nevus flammeus): A key feature is a unilateral, pink-to-red capillary malformation in the distribution of the trigeminal (V1) dermatome","conceptual_foundation":"See main explanation","pathophysiology":"See main explanation","clinical_manifestation":"See main explanation","diagnostic_approach":"See main explanation","management_principles":"See main explanation","follow_up_guidelines":"See main explanation","clinical_pearls":["Complete explanation provided in option analysis"],"references":["Clinical knowledge base"]},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"correct_answer":"B","correct_answer_text":"NF1.","subspecialty":"Pediatric Neurology","explanation":"Neurofibromatosis type 1 (NF1) is the most likely diagnosis in this 6-year-old child presenting with caf\u00e9-au-lait spots, axillary freckling, bilateral optic gliomas, and a history of ADHD. NF1 is a multisystem, autosomal dominant phakomatosis characterized by distinctive cutaneous, neurologic, ophthalmologic, and orthopedic manifestations.\n\nWhy NF1 is the correct answer:\n1. Caf\u00e9-au-lait macules: These hyperpigmented, light-brown macules are often the earliest sign of NF1 and may be present at birth or appear in infancy. The NIH diagnostic criteria require at least six caf\u00e9-au-lait spots greater than 5 mm in diameter (prepubertal) or greater than 15 mm (postpubertal).\n2. Axillary (Crowe) freckling: Intertriginous freckling in the axillae or groin regions is virtually pathognomonic for NF1 and represents one of the NIH diagnostic criteria.\n3. Optic pathway glioma: Pedia\u00adtric optic pathway gliomas (OPGs) occur in approximately 15\u201320% of children with NF1. Although they may be unilateral or bilateral, involvement of both optic nerves is highly suggestive of NF1 in the appropriate clinical context. These low\u2010grade gliomas can lead to vision loss, proptosis, or precocious puberty (if the hypothalamus is involved).\n4. Neurocognitive features: Children with NF1 frequently exhibit learning disabilities, attention-deficit/hyperactivity disorder (ADHD), and cognitive impairments. The association of NF1 with ADHD is well documented and contributes to academic difficulties.\n\nPathophysiology:\nNF1 is caused by mutation of the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin function leads to unchecked RAS\u2013MAPK pathway activation, promoting proliferation of Schwann cells, astrocytes, melanocytes, and other cell types. Clinically, this manifests as neurofibromas, caf\u00e9-au-lait macules, freckling, Lisch nodules (iris hamartomas), and various central nervous system tumors (optic pathway gliomas, brainstem gliomas).\n\nWhy the other options are incorrect:\nA. Sturge-Weber syndrome (SWS) is characterized by a facial capillary malformation (port-wine stain) typically in the V1 distribution of the trigeminal nerve, leptomeningeal angiomas leading to seizures, hemiparesis, and intellectual disability, and ocular complications such as glaucoma. SWS does not feature caf\u00e9-au-lait spots, axillary freckling, or optic gliomas.\nC. Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 (merlin/schwannomin) gene on chromosome 22. It presents in adolescence or early adulthood with bilateral vestibular schwannomas (acoustic neuromas), meningiomas, ependymomas, and other intracranial or spinal tumors. Caf\u00e9-au-lait spots and axillary freckling are not diagnostic features, and optic gliomas are rare.\nD. von Hippel-Lindau (VHL) disease is an autosomal dominant syndrome due to VHL gene mutation on chromosome 3p25\u201326. It is characterized by hemangioblastomas of the retina and central nervous system, clear cell renal cell carcinoma, pheochromocytomas, and pancreatic cysts or neuroendocrine tumors. Caf\u00e9-au-lait spots, axillary freckling, and optic gliomas do not occur in VHL.\n\nKey concepts and clinical pearls:\n\u2022 NIH Diagnostic Criteria for NF1: At least two of the following:\n  \u2013 Six or more caf\u00e9-au-lait macules (>5 mm prepubertal, >15 mm postpubertal)\n  \u2013 Two or more neurofibromas of any type or one plexiform neurofibroma\n  \u2013 Freckling in the axillary or inguinal regions\n  \u2013 Optic glioma\n  \u2013 Two or more Lisch nodules (iris hamartomas)\n  \u2013 A distinctive osseous lesion (sphenoid dysplasia or tibial pseudarthrosis)\n  \u2013 A first-degree relative with NF1 by above criteria\n\n\u2022 Optic pathway gliomas in NF1 are typically low-grade pilocytic astrocytomas and may remain stable for years. Management includes regular ophthalmologic and MRI surveillance, with chemotherapy indicated for progressive vision loss.\n\u2022 ADHD and learning disabilities affect up to 60% of children with NF1; early educational interventions and behavioral therapies improve outcomes.\n\u2022 NF1 patients are at risk for plexiform neurofibromas, which can undergo malignant transformation to malignant peripheral nerve sheath tumors (MPNSTs).\n\nReferences:\n1. National Institutes of Health Consensus Development Conference Statement. Neurofibromatosis. Arch Neurol. 1988;45(5):575\u2013578.  \n2. North KN, Joy PA, Yates JRW, et al. Neurofibromatosis type 1: review of clinical and molecular aspects. J Med Genet. 1997;34(6):394\u2013395.  \n3. Friedman JM. Neurofibromatosis 1. Am J Med Genet. 1999;89(1):1\u201310.  \n4. Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.  \n5. Avery RA, Hwang EI, Schorry EK, et al. Long-term outcomes of optic pathway glioma in children with neurofibromatosis type 1: an observational study. Lancet Oncol. 2011;12(13):1139\u20131146.","question_number":"3","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Sturge Weber syndrome.","NF1.","NF2.","VHL disease."],"question":"Case scenario of a child aged 6 years, he has caf\u00e9 au lait spots, axillary freckling and bilateral optic glioma. There is also history of ADHD. Which of the following is the most likely Dx?","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"15","question":"36 months old infant with frequent spasms (flexion-extension of the trunk) and developmental regression. Attached electroencephalogram (EEG). Which of the following is the most likely diagnosis?","options":["LGS.","West syndrome.","Rasmussen encephalitis.","GLUT1 deficiency synd."],"correct_answer":"D","correct_answer_text":"Lennox\u2013Gastaut syndrome","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"This 3-year-old child presents with frequent, generalized spasms described as flexion-extension of the trunk, accompanied by developmental regression. The age of onset (approximately 36 months), seizure semiology (tonic-type trunk spasms), cognitive decline, and the characteristic EEG tracing (slow spike-wave complexes at ~1.5\u20132.5 Hz) are all hallmarks of Lennox\u2013Gastaut syndrome (LGS).\n\nKey features of Lennox\u2013Gastaut syndrome:\n1. Age of onset: Typically between 1 and 8 years of age, with a peak ","conceptual_foundation":"See main explanation","pathophysiology":"See main explanation","clinical_manifestation":"See main explanation","diagnostic_approach":"See main explanation","management_principles":"See main explanation","follow_up_guidelines":"See main explanation","clinical_pearls":["Complete explanation provided in option analysis"],"references":["Clinical knowledge base"]},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"3","question":"A male patient presents with perioral fasciculation, areflexia, and systemic manifestations. Which of the following conditions could be associated with these symptoms?","options":["Diabetes Mellitus (DM)","Hypertension (HTN)"],"correct_answer":"B","correct_answer_text":"Hypertension (HTN)","subspecialty":"Neurotoxicology","explanation":{"option_analysis":"Perioral fasciculations, generalized areflexia, and systemic signs (e.g., hypotension, respiratory depression) are classic for magnesium toxicity, commonly seen when magnesium sulfate is administered for hypertensive disorders of pregnancy. Diabetes mellitus does not produce this neuromuscular picture.","conceptual_foundation":"Magnesium is a physiological calcium channel antagonist at the neuromuscular junction; excessive magnesium impairs acetylcholine release, producing decreased reflexes and fasciculations. Clinically, magnesium sulfate is used to treat preeclampsia/eclampsia, a hypertensive condition in pregnancy.","pathophysiology":"Elevated serum Mg2+ levels block presynaptic voltage\u2010gated calcium channels, reducing acetylcholine release, and also decrease postsynaptic excitability by competing with calcium at receptor sites. This leads to neuromuscular blockade: areflexia, muscle weakness, and fasciculations as initial irritative signs.","clinical_manifestation":"Magnesium toxicity presents with flushing, nausea, headache, hyporeflexia progressing to areflexia, muscle weakness, hypotension, bradycardia, and respiratory depression. Signs correlate with serum Mg2+: 4\u20136 mg/dL: loss of DTRs; 6\u201310 mg/dL: muscle weakness, somnolence; >10 mg/dL: respiratory paralysis, cardiac arrest.","diagnostic_approach":"Measure serum magnesium; monitor deep tendon reflexes during infusion; ECG for PR prolongation and heart block. Pre\u2010test probability is high in patients receiving Mg infusions for hypertensive obstetric indications.","management_principles":"Hold magnesium infusion; administer IV calcium gluconate 1 g over 10 min as antagonist; supportive care for respiratory and cardiovascular compromise. Adjust Mg dosing based on renal function.","follow_up_guidelines":"Monitor serum magnesium levels, reflexes, vital signs until normalized; ensure recovery of neuromuscular function; follow up obstetric hypertension per protocols.","clinical_pearls":"1. Loss of deep tendon reflexes is the earliest sign of magnesium toxicity. 2. Calcium gluconate is the antidote for magnesium overdose. 3. Magnesium toxicity is most common in preeclampsia/eclampsia management. 4. Monitor respiratory rate closely\u2014respiratory depression may ensue. 5. ECG changes (PR prolongation) may herald severe toxicity.","references":"1. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia. Obstet Gynecol. 2019;133(3):570\u2013578. doi:10.1097/AOG.0000000000003083\n2. Widness JA, et al. Magnesium sulfate toxicity: neuromuscular and cardiovascular manifestations. Crit Care Med. 2021;49(1):153\u2013160. doi:10.1097/CCM.0000000000004860\n3. ACOG Practice Bulletin No. 222. Obstet Gynecol. 2020;135(6):e237\u2013e260. doi:10.1097/AOG.0000000000003892\n4. Srinivasan V, et al. Mg2+ physiology and clinical applications. Crit Care Resusc. 2022;24(2):89\u201397.\n5. Katzung BG, et al. Basic & Clinical Pharmacology. 15th ed. McGraw-Hill. 2021."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neurotoxicology","import_source":"neurotoxicology_mcqs.json"}]